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Introduction
Cervical cancer (CC) is the second most common 
malignancy in Tunisia and a public health inquiry 
in women worldwide. In some African and Asian 
countries like China, its morbidity still ranks the first in 
gynaecological malignant tumors (Li et al., 2011; Wang 
et al., 2013; Wang et al., 2013; Mvundura and Tsu, 2014), 
leading to a revising scheme of preventive strategy (Al 
Moustafa et al., 2014) including vaccination (Othman et 
al., 2014; Hanley et al., 2014). Human Papillomaviruses 
(HPVs) have been recognized as its etiologic factor (Zur 
Hausen, 2009) and are classified as low risk and high-risk 
HPVs (HR-HPVs), the latter being associated with cervical 
intraepithelial neoplasia (CINs), mainly HPV16 and 18 
that possess a high potential for progression into invasive 
squamous cells cervical carcinoma (ISCC). Development 
of CIN and ISCC from normal cervical tissue is a gradual 
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Abstract
 Toll-like receptors (TLRs) are expressed in immune and tumor cells and recognize pathogen-associated 
molecular patterns. Cervical cancer (CC) is directly linked to a persistent infection with high risk human 
papillomaviruses (HR-HPVs) and could be associated with alteration of TLRs expression. TLR9 plays a key role 
in the recognition of DNA viruses and better understanding of this signaling pathway in CC could lead to the 
development of novel immunotherapeutic approaches. The present study was undertaken to determine the level 
of TLR9 expression in cervical neoplasias from Tunisian women with 53 formalin-fixed and paraffin-embedded 
specimens, including 22 samples of invasive cervical carcinoma (ICC), 18 of cervical intraepithelial neoplasia 
(CIN), 7 of condyloma and 6 normal cervical tissues as control cases. Quantification of TLR9 expression was 
based on scoring four degrees of extent and intensity of immunostaining in squamous epithelial cells. TLR9 
expression gradually increased from CIN1 (80% weak intensity) to CIN2 (83.3% moderate), CIN3 (57.1% 
strong) and ICC (100% very strong). It was absent in normal cervical tissue and weak in 71.4% of condyloma. 
The mean scores of TLR9 expression were compared using the Kruskall-Wallis test and there was a statistical 
significance between normal tissue and condyloma as well as between condyloma, CINs and ICC. These results 
suggest that TLR9 may play a role in progression of cervical neoplasia in Tunisian patients and could represent 
a useful biomarker for malignant transformation of cervical squamous cells.  
Keywords: Toll - like receptors - TLR9 - cervical cancer - immunohistochemistry
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process and is directly linked to persistent HR-HPV 
infection (Wang et al., 2013) but determinant factors 
for viral persistence and tumorogenic progression are 
ill-understood. Tumor associated inflammation have a 
key role in CC development (Boccardo et al., 2010) and 
an inflammatory related biomarker that can be predictive 
for CC progression and development could give good 
opportunities for novel therapeutic approaches. Toll-
like receptors (TLRs) are important families of pattern 
recognition receptors, which recognize conserved 
components of microorganisms and trigger the immune 
response against invading pathogens (Zhou et al., 2013). 
The essential role of TLRs in the activation of the immune 
system was a revolutionary finding awarded in 2011 by 
the Nobel Prize for medicine (Wagner, 2012). Among 
them, TLR9 has been demonstrated as an important 
receptor of recognition against DNA invading pathogens 
and especially several DNA virus, inducing inflammatory 
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and immune responses (Lund et al., 2003; Krug et al., 
2004). Most of the previous reports have focused on their 
expression and function in cells of the immune system like 
B-lymphocytes and plasmacytoid dendritic cells. Current 
works are focusing on their association with cancers 
(Domingos-Pereira et al., 2013; Bodelon et al., 2014) 
and the use of vaccine with TLR agonist or antagonist in 
cervical cancer is now undergoing extensive investigations 
(Geller et al., 2010; Mai et al., 2013; Sajadian et al., 2014). 
Several previous works have shown that TLR9 signaling 
promotes tumor growth, survival and immune evasion in 
CC as in many other cancer types, such as gastric cancer 
(Schmausser et al., 2005), prostatic cancer (Gonzalez-
Reyes et al., 2011) breast cancer (Bhattacharya and Yusuf, 
2012), lung cancer (Ren et al., 2007), glioma (Wang et 
al., 2010), and oesophageal squamous cell carcinoma 
(Sheyhidin et al., 2011). But it has also been suggested to 
have anti-tumor activities (Chang et al, 2014) and whether 
TLR9 promotes or suppress cancer development remains 
under discussion, leading to investigations about TLR 
polymorphism and genetic variations of TLR pathway 
(Oliveira et al., 2013; Bodelon et al.,2014). The present 
study aims to evaluate the expression levels of TLR9 on 
Tunisian cervical samples in gradual stages of CINs and 
ISCC using normal cervical tissues and condyloma as 
control cases. 
Materials and Methods
Tissues samples
53 archival (2008-2012) formalin fixed and paraffin-
embedded tissues derived from cervical biopsies, 
conization or hysterectomy specimens collected from 
the files of the Department of Human and Experimental 
Pathology of Pasteur Institute of Tunis and five departments 
of pathology from the Northern, Central and Southern 
Tunisian hospitals were used in this study. All tissue 
sections were rechecked for pathological assessment of 
diagnosis in the Laboratory of Human and Experimental 
Pathology of Pasteur Institute of Tunis before the 
immunohistochemical assay. Eighteen subjects were 
diagnosed with different stages of CIN, including 5 CIN1, 
6 CIN2, 7 CIN3 and were compared to 22 cases of ISCC, 
7 condyloma and 6 samples of normal cervical squamous 
epithelium to serve as control cases. 
Immunohistochemistry
Tissue sections 4µm thick were cut from formalin-
fixed, paraffin-embedded blocks and were used to prepare 
routine histopathology and immunohistochemistry (IHC) 
slides. Sections were mounted on glass slide, deparaffinised 
in toluene (2×15 min) and rehydrated with ethanol. To 
increase specificity and sensitivity, slides were processed 
for antigen retrieval by boiling in 10 mmol/L citrate buffer 
(pH 6.0), 30 min in 96°C bain-marie and then left to cool 
for 25 min, rinsed in running water for 1min and dipped 
in distilled water for 2-3 dips. Endogenous peroxidase 
activity was blocked by a15 min incubation in peroxydase 
block (Leica kit NovolinkTM Max polymer detection 
system). Sections were washed in PBS (7.75 g Tris-HCl 
pH 7.5, 8.78 g NaCl ad 1 liter H2O) and incubated for 15 
min in protein block buffer provided in the kit. They were 
then incubated with an anti-TLR9 monoclonal antibody 
(Imgenex Cat.No IMG-305A, clone 26C593) at a 1/250 
dilution for 45 min at room temperature, washed in PBS 
and incubated in post- primary Block buffer (Novocastra 
Leica Microsystems) for 30 minutes. Sections were 
rinsed in 1×Tris and incubated with Novocastra polymer 
for 30 min at room temperature. Bound antibodies were 
stained with AEC solution (Sigma) and counterstained 
with Hemalun (Merck). The slides were rinsed 3 times 
in bidistilled water and mounted on glass slides using 
Eukitt (Merck). 
Two histopathologists blindly reviewed the slides 
and evaluated the immunohistochemical data under 
light microscopy with photography. Red or purple-red 
color in the cytoplasm of cells was defined as TLR9 
positive staining. Based on the staining intensity and the 
distribution and the proportion of TLR9 positive cells in 
squamous epithelium, TLR9 immunoreactivity was scored 
on a scale from 0 to 4+ as follow: 0: no positive staining 
cells; 1+: less than 50% of cells with weak intensity; 2+: 
more than 50% of cells with moderate intensity; 3+: more 
than 50% of cells with strong intensity; 4+ : more than 
80% of cells with very strong intensity. 
Statistical analysis
SPSS 13.0 (SPSS, Inc., Chicago, IL, USA) was used 
for statistical analysis of the data. The mean scores of 
TLR9 expression in normal cervical epithelia, condyloma, 
CIN1, CIN2, CIN3 and ISCC were compared with the 
Kruskal-Wallis test (p<0.05).
Results 
Immunohistochemistry
TLR9 immunoreactivity was intracellular (Figure 
1). None of the 6 normal cervical tissue samples was 
stained (Figure 1B). TLR9 expression was detected in 
all slides of condyloma, CINs and ISCC. The intensity 
of immunostaining was constantly increasing from 
condyloma to ISCC. Staining intensity was weak in 
71.4% of condyloma, and involved koïlocytic cells and 
some of the medium layer epithelial cells (Figure 1D). 
Weak intensity of staining was observed in 80% of CIN1 
and was mostly involving the lower third epithelial layer 
(Figure 1F). 83.3% of CIN2 expressed TLR9 protein with 
a moderate intensity in the two lower thirds epithelial 
layers. Immunostaining was strong in 71.4% of CIN3, 
involving all epithelial layers (Figure 1J). All samples of 
ISCC displayed a very strong and diffuse staining (Figure 
1L). There was also a strong expression of TLR9 in many 
of the stromal inflammatory cells. Distribution of TLR9 
scoring according to the degree of immunoreactivity is 
detailed in Table 1.
Statistical results
The mean scores of TLR9 expression were clearly 
increasing from condyloma to CIN1, 2, 3 and ISCC 
(Figure 2). Statistical analysis of the immunostaining 
scores of TLR9 in the different cervical samples using 
the non parametric kruskall-Wallis test (Table1) showed 
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a significant increasing from normal cervical tissue to 
condyloma, CINs and ISCC, from condyloma to CIN3 
and ISCC and from CIN1 and CIN2 to ISCC (p<0.05). 
The intensity of TLR9 staining in CIN3 and ISCC was 
similar. The mean scores of TLR9 imunoreactivity that 
were increasing from CIN1 to CIN2 and CIN3 was not 
statistically significant (Table 2). 
Discussion
Cervical cancer is a major health inquiry in developing 
countries where Pap smear screening has not been 
successful to control the disease and HPV vaccine 
implementation is lacking cost-effectiveness studies. 
Immunotherapeutic approaches could give alternative 
Figure 1. Hematoxylin and Eosin (HE) Staining and 
Expression of TLR9 Detected by Immunohistochemistry 
in the Tested Samples (High Power field x400). A) 
Normal cervical squamous epithelium serving as control cases; 
B) No TLR9 staining was detected in the control; C) Koilocytic 
changes in cervical epithelium of condyloma; D) Some of the 
koilocytic cells were weakly stained in condyloma; E) Atypical 
cells are restricted within lower third of squamous epithelium 
in CIN1; F) Moderate immunoreactivity of TLR9 within lower 
third of squamous epithelium in CIN1; G) Atypical cells are 
seen in lower two thirds of squamous epithelium in CIN2; H) 
immunoreactivity of TLR9 within two lower third of squamous 
epithelium in CIN2; I) Atypical cells exceeded lower two thirds 
of squamous epithelium in CIN3; J) Strong immunoreactivity 
of TLR9 diffusely distributed within the atypical layers of 
the cervical epithelium in CIN3. K) Cancer nests invaded 
into cervical wall in ISCC; L) Very strong and diffuse TLR9 
expression in tumor epithelial cells of invasive carcinoma. 
Stromal inflammatory cells were stained too
 A) B)
 C) D)
 E) F)
 G) H)
 I) J)
 K) L)
Table 1. Expression of TLR9 in Normal, Condyloma, 
CIN1, 2, 3 and ISCC
Tissues  Degree of immunoreactivity
 0 1+ 2+ 3+ 4+
Normal 6/6(100) 0/6(0) 0/6(0) 0/6(0) 0/6(0)
Condyloma 1/7(14.2) 5/7(71.4) 1/7(14.2) 0/7(0) 0/7(0)
CIN1  0/5(0) 4/5(80) 1/5(20) 0/5(0) 0/5(0)
CIN2 0/6(0) 1/6(16.6) 5/6(83.3) 0/6(0) 0/6(0)
CIN3 0/7(0) 1/7(14.2) 1/7(14.2) 4/7(51.7) 1/7(14.2)
ISCC 0/22(0) 0/22(0) 0/22(0) 0/22(0) 22/22(100)
Table 2. Results of Multiple Comparaison of P value
 Lesion p value
 normalxcondylome <0.05
 nomalxCIN1 <0.05
 normalxCIN2 <0.05
 normalxCIN3 <0.05
 normalxISCC <0.05
 condylomexCIN1 >0.05
 condylomexCIN2 >0.05
 condylomexCIN3 <0.05
 condylomexISCC <0.05
 CIN1xCIN2 >0.05
 CIN1xCIN3 >0.05
 CIN1xISCC <0.05
 CIN2xCIN3 >0.05
 CIN2xISCC <0.05
 CIN3xISCC >0.05
Figure 2. Mean Scores of TLR9 Expression According 
to the Grade of Neoplasia of the Cervix. The expression of 
TLR9 was increasing from normal cervical tissue to condyloma 
and CINs to invasive carcinoma (IC), Error bars: 95,00 CI
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means for CC control and Toll-like receptors pathway 
appears as a good field of research. It has been demonstrated 
that under some conditions, TLRs expressed by tumors 
cells do play a pivotal role in regulating tumor growth, 
activating innate immunity against invading pathogens 
and cytokine production (Yu et al., 2013). TLR9 is an 
important receptor of recognition against DNA viruses 
(Zolini et al., 2014) and although a first study was 
consistent with the lack of relation between HPV and 
TLR9 expression and function (Andersen et al., 2006), 
it has been later demonstrated to be expressed in HPV-
positive cervical neoplasia on human foreskin, vaginal 
and cervical keratinocytes cell lines maintaining episomal 
copies of HPV16 and 18, in several CC derived cell 
lines and in formalin-fixed paraffin-embedded or frozen 
cervical tissue sections (Karim et al., 2011; Werner et al., 
2012). In this series, immunohistochemical scoring of 
TLR9 staining using a monoclonal antibody has shown 
that TLR9 expression is detected in all condyloma, CINs 
and ISCC with a significant gradual increasing level of 
expression from CIN1 to ISCC. Staining was weak in 80% 
of the CIN1 and moderate in 83.3% of CIN2, becoming 
strong in 71.4% of CIN3 to very strong in all ISCC. There 
was not any TLR9 expression among 6 normal cervical 
tissues and staining was weak in most of condyloma. Our 
findings were consistent with other reports (Lee et al., 
2007; Hasimu et al., 2011; DeCarlo et al., 2012) which 
also used formalin-fixed and paraffin-embedded tissue 
specimens providing from Korean, Chinese and Canadian 
women. They have shown an increasing expression 
of TLR9 in neoplastic cervical epithelia in the course 
of progression of the disease, suggesting that TLR9 
upregulation could be beneficial to tumor progression and 
invasiveness of cervical tissue. An increasing expression 
of TLR5 and more recently of TLR4 in CC is also reported 
(Kim et al., 2008; Chen et al 2012; Mai et al 2013). The 
possible way of action could be an increase of tumor pro-
growth conditions through a selective pressure of the pro-
inflammatory local microenvironment. TLR9 recognizes 
the ODN with CpG motif and after binding with the 
ligand, it may facilitate an immune evasion through 
inhibitory cytokines, inflammatory factors, proteinases, 
and other small molecules such as nitric oxide, IL-6 and 
IL-12 mimicking some characteristics of inflammatory 
cells. Their action can lead to resistance of tumor cells 
to CTL and natural killer attacks and evasion from 
immune surveillance (Zhou et al., 2013). The existence 
of opposite data in different ethnic population specimens 
makes a major problem in understanding the role of TLR9 
signaling pathway in CC (Yu et al 2010; DeCarlo et al., 
2012). It has been reported a decrease of TLR9 mRNA 
levels with cervical disease severity (Yu et al., 2010) or a 
gradual decrease in TLR9 expression along with the grade 
of CIN suggesting TLR9 expression as an early event in 
the development of CC in Mexican women (Moreno-
Eutimio et al., 2013). Other studies have demonstrated an 
increase of TLR9 expression with HPV clearance (Daud et 
al., 2011). TLR9 expression and function can be abolished 
by HPV16 when using a quantification of TLR9 on cancer 
derived cell lines infected by HPV16 E6 and E7 proteins 
(Hasan et al., 2007; Hasan et al., 2013) and speculate 
that HPV may use TLR9 dysregulation as a strategy 
to avoid viral recognition. The interaction between 
HPV and components of the tumor microenvironment 
could impair TLR9 signaling and downregulate TLR9 
gene expression leading to the reduction of the innate 
immune responses during chronic viral infections. New 
therapeutic approaches based on TLR agonists have then 
been proposed (Hirsch et al., 2010; Ohlschlager et al., 
2011; Domingos-Pereira et al., 2013). The same inequity 
has been shown in other cancer types. Some authors has 
suggested an abnormal activation of TLRs on tumor 
cells that are associated with immune tolerance, tumor 
progression and propagation in oesophageal squamous 
cell carcinoma (Sheyhidin et al., 2011), pancreatic 
carcinogenesis (Ochi et al., 2012), colorectal cancer 
(Doan et al., 2011), breast cancer (Yang et al., 2010), 
lung cancer (Ren et al., 2007) and glioma (Wang et al., 
2010). At the opposite, a protective action of TLR9 and 
TLR3 has been described in experimental models of 
glioma (El andaloussi et al., 2006), in a mouse model of 
colitis-associated colon cancer (Liu et al., 2010) and in 
chronic lymphatic leukemia (Spaner and Masellis, 2007). 
TLRs pathway is supposed here to provide signals that 
are necessary for the resolution of inflammation and TLR 
agonists have also been proposed as a good opportunity 
for cancer treatment as effective immune adjuvants or 
combined immunotherapy or as a modulator of cervical 
cancer cells chemosensitivity (Schmidt, 2006; Weng et 
al., 2011; Mason and Hunter, 2012). TLRs pathway could 
then induce different signals in CC as in other cancer 
types that could promote or inhibit tumour progression. 
The complicated interaction between tumor cells, immune 
cells pathogen-associated molecular patterns in the tumor 
microenvironment could promote either tumor progression 
or apoptosis and cancer regression. The reasons for those 
discrepancies are not clear but genetic variations of TLR9 
pathway through a polymorphism in some TLR9 regions 
is now under question (Pandey et al., 2011; Roszak et al., 
2012; Chen et al., 2012; Oliveira et al., 2013; Lai et al., 
2013; Bodelon et al., 2014) and it seems now likely to 
talk about cancer susceptibility and TLR9 polymorphism 
(Chen et al., 2012; Dai et al., 2014). Our results suggest 
that TLR9 may play a role in progression of cervical 
neoplasia in Tunisian patient and could represent a useful 
biomarker for malignant transformation of cervical cells.
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